The effects of chronic naloxone on pituitary hormone secretion in female rats

S. M. Gabriel; J. W. Simpkins; W. J. Millard

doi:10.1016/0361-9230(84)90104-7

The effects of chronic naloxone on pituitary hormone secretion in female rats

S. M. Gabriel, J. W. Simpkins, W. J. Millard

Friedman Brain Institute

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The effects of a sustained-release implant for naloxone (NAL) on serum concentrations of prolactin (PRL), immunoreactive β-endorphin (IR-β-ENDO), growth hormone (GH) and thyroid stimulating hormone (TSH) were evaluated in ovariectomized female rats. After 9 days of exposure to NAL, serum levels of none of these 4 pituitary hormones were altered. However, the NAL implant antagonized the stimulatory effects of morphine (15 and 30 mg/kg body weight) on PRL and IR-β-ENDO secretion, enhanced the stimulatory effects of morphine on GH secretion, and had no effect on morphine-induced suppression of TSH secretion. These results indicate that while chronic NAL exposure does not, by itself, persistently alter pituitary hormone secretion, it differentially effects the response of these hormones to morphine exposure. These data suggest that chronic treatment with narcotic antagonists may invoke differential compensatory mechanisms to maintain normal hormone secretion.

Original language	English
Pages (from-to)	359-362
Number of pages	4
Journal	Brain Research Bulletin
Volume	12
Issue number	4
DOIs	https://doi.org/10.1016/0361-9230(84)90104-7
State	Published - Apr 1984

Keywords

Growth hormone
Morphine
Naloxone
Narcotic antagonist
Opiates
Prolactin
Sustained-release
Thyroid stimulating hormone
β-Endorphin

Access to Document

10.1016/0361-9230(84)90104-7

Cite this

@article{01ec2f2a1d8e46b1b0345052b83d4bc9,

title = "The effects of chronic naloxone on pituitary hormone secretion in female rats",

abstract = "The effects of a sustained-release implant for naloxone (NAL) on serum concentrations of prolactin (PRL), immunoreactive β-endorphin (IR-β-ENDO), growth hormone (GH) and thyroid stimulating hormone (TSH) were evaluated in ovariectomized female rats. After 9 days of exposure to NAL, serum levels of none of these 4 pituitary hormones were altered. However, the NAL implant antagonized the stimulatory effects of morphine (15 and 30 mg/kg body weight) on PRL and IR-β-ENDO secretion, enhanced the stimulatory effects of morphine on GH secretion, and had no effect on morphine-induced suppression of TSH secretion. These results indicate that while chronic NAL exposure does not, by itself, persistently alter pituitary hormone secretion, it differentially effects the response of these hormones to morphine exposure. These data suggest that chronic treatment with narcotic antagonists may invoke differential compensatory mechanisms to maintain normal hormone secretion.",

keywords = "Growth hormone, Morphine, Naloxone, Narcotic antagonist, Opiates, Prolactin, Sustained-release, Thyroid stimulating hormone, β-Endorphin",

author = "Gabriel, {S. M.} and Simpkins, {J. W.} and Millard, {W. J.}",

note = "Funding Information: The authors wish to thank DuPont Pharmaceuticals( Garden Citv. NY) for the aenerouss ift of naloxoneH Cl and the Fituitarv Ho&one{\textquoteright}Distrib&on Frog& of NIADDK for the RIA Kits used. We are indebteda lso to Drs. GeorgeT orosian, Kenneth Sloan and Hartmut Derendorff or their assistanced uringthe preparationa nd analysis of the naloxonep ellets. The secretariala id of Ms. Fran PanieRoi s greatIya ppreciatedT. his work was supportedin part by NIH grant AGO2021a nd grant HD 17364.",

year = "1984",

month = apr,

doi = "10.1016/0361-9230(84)90104-7",

language = "English",

volume = "12",

pages = "359--362",

journal = "Brain Research Bulletin",

issn = "0361-9230",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - The effects of chronic naloxone on pituitary hormone secretion in female rats

AU - Gabriel, S. M.

AU - Simpkins, J. W.

AU - Millard, W. J.

N1 - Funding Information: The authors wish to thank DuPont Pharmaceuticals( Garden Citv. NY) for the aenerouss ift of naloxoneH Cl and the Fituitarv Ho&one’Distrib&on Frog& of NIADDK for the RIA Kits used. We are indebteda lso to Drs. GeorgeT orosian, Kenneth Sloan and Hartmut Derendorff or their assistanced uringthe preparationa nd analysis of the naloxonep ellets. The secretariala id of Ms. Fran PanieRoi s greatIya ppreciatedT. his work was supportedin part by NIH grant AGO2021a nd grant HD 17364.

PY - 1984/4

Y1 - 1984/4

N2 - The effects of a sustained-release implant for naloxone (NAL) on serum concentrations of prolactin (PRL), immunoreactive β-endorphin (IR-β-ENDO), growth hormone (GH) and thyroid stimulating hormone (TSH) were evaluated in ovariectomized female rats. After 9 days of exposure to NAL, serum levels of none of these 4 pituitary hormones were altered. However, the NAL implant antagonized the stimulatory effects of morphine (15 and 30 mg/kg body weight) on PRL and IR-β-ENDO secretion, enhanced the stimulatory effects of morphine on GH secretion, and had no effect on morphine-induced suppression of TSH secretion. These results indicate that while chronic NAL exposure does not, by itself, persistently alter pituitary hormone secretion, it differentially effects the response of these hormones to morphine exposure. These data suggest that chronic treatment with narcotic antagonists may invoke differential compensatory mechanisms to maintain normal hormone secretion.

AB - The effects of a sustained-release implant for naloxone (NAL) on serum concentrations of prolactin (PRL), immunoreactive β-endorphin (IR-β-ENDO), growth hormone (GH) and thyroid stimulating hormone (TSH) were evaluated in ovariectomized female rats. After 9 days of exposure to NAL, serum levels of none of these 4 pituitary hormones were altered. However, the NAL implant antagonized the stimulatory effects of morphine (15 and 30 mg/kg body weight) on PRL and IR-β-ENDO secretion, enhanced the stimulatory effects of morphine on GH secretion, and had no effect on morphine-induced suppression of TSH secretion. These results indicate that while chronic NAL exposure does not, by itself, persistently alter pituitary hormone secretion, it differentially effects the response of these hormones to morphine exposure. These data suggest that chronic treatment with narcotic antagonists may invoke differential compensatory mechanisms to maintain normal hormone secretion.

KW - Growth hormone

KW - Morphine

KW - Naloxone

KW - Narcotic antagonist

KW - Opiates

KW - Prolactin

KW - Sustained-release

KW - Thyroid stimulating hormone

KW - β-Endorphin

UR - http://www.scopus.com/inward/record.url?scp=0021196021&partnerID=8YFLogxK

U2 - 10.1016/0361-9230(84)90104-7

DO - 10.1016/0361-9230(84)90104-7

M3 - Article

C2 - 6329481

AN - SCOPUS:0021196021

SN - 0361-9230

VL - 12

SP - 359

EP - 362

JO - Brain Research Bulletin

JF - Brain Research Bulletin

IS - 4

ER -

The effects of chronic naloxone on pituitary hormone secretion in female rats

Abstract

Keywords

Access to Document

Fingerprint

Cite this